معرفی
Jonas Oldgren is Professor at the Department of Medical Sciences, specializing in Cardiology at Uppsala University. He also serves as a Researcher at the UCR-Uppsala Clinical Research Center. His primary research focuses on atrial fibrillation, stroke prevention, anticoagulation therapy, and cardiovascular biomarkers. Oldgren actively contributes to major clinical trials and registry studies, particularly in the field of cardiovascular risk stratification.
Oldgren's research interests center on developing and validating risk prediction models for patients with atrial fibrillation. His work has been instrumental in creating the ABC (Age, Biomarkers, Clinical history) risk scores for predicting stroke, bleeding, and mortality in atrial fibrillation patients. He investigates how biomarkers can improve traditional risk assessment methods and personalize treatment decisions, particularly regarding anticoagulation therapy. His research spans clinical trial design, registry-based studies, and biomarker validation across diverse patient populations.
Analysis of his recent publications reveals a strong focus on personalized medicine approaches in cardiology, particularly in atrial fibrillation management. His work frequently involves large-scale registry studies and randomized controlled trials across multiple European countries. Key themes include optimizing timing of anticoagulation therapy after stroke, developing biomarker-based risk scores, investigating novel anticoagulants like asundexian, and understanding sex differences in cardiovascular disease presentation and outcomes.
While no specific scientific awards are listed in the provided information, Oldgren's extensive publication record in high-impact journals including The Lancet, New England Journal of Medicine, and Circulation demonstrates significant recognition in his field. His collaborative work with major cardiovascular research consortia indicates substantial influence on clinical practice guidelines.
Oldgren has served as principal investigator and co-investigator on numerous large-scale clinical trials including the TIMING, CATALYST, DAPA-MI, and INFINITY-SWEDEHEART studies. His research is frequently supported by major funding bodies and pharmaceutical collaborations focused on advancing cardiovascular therapeutics and risk assessment. He actively participates in the design and execution of registry-based randomized trials, which represent an innovative approach to clinical research methodology.
As part of the UCR-Uppsala Clinical Research Center, Oldgren collaborates with a multidisciplinary team of cardiologists, epidemiologists, biostatisticians, and laboratory scientists. His work connects closely with the Swedish Heart-Warfarin Registry and other national cardiovascular registries, leveraging real-world data to inform clinical practice. The research environment supports his focus on translational cardiology, bridging the gap between biomarker discovery and clinical implementation.
